Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00298779 · ClinicalTrials.gov registry record · Phase 1

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

A Phase 1 study, sponsored by Millennium Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT00298779 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00298779, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

This is an open-label, randomized, multiple-dose, multicenter Pharmacokinetics drug-drug interaction study in patients with advanced solid tumors, including non-Hodgkin's lymphoma, who are in need of anti-tumor therapy. In addition, the impact of omeprazole on the pharmacodynamics of VELCADE will also be evaluated.

Interventions

  • DRUG omeprazole and bortezomib

Trial Details

FieldValue
Enrollment Target 20 participants
Phase Phase 1

Sponsor

Millennium Pharmaceuticals

135 total trials

What the Registry Record Tells You About NCT00298779

The ClinicalTrials.gov registry entry for NCT00298779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which omeprazole and bortezomib is the first listed.

NCT00298779 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00298779 about?

NCT00298779 is a clinical study titled "Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.". This is an open-label, randomized, multiple-dose, multicenter Pharmacokinetics drug-drug interaction study in patients with advanced solid tumors, including non-Hodgkin's lymphoma, who are in need of anti-tumor therapy. In addition, the impact of omeprazole on the pharmacodynamics of VELCADE will al...

What is the current status of trial NCT00298779?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants.

What interventions are being tested in trial NCT00298779?

The interventions under investigation include: omeprazole and bortezomib (DRUG).

Who is sponsoring clinical trial NCT00298779?

This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.